A new peer-reviewed COVID-19 vaccine study is drawing national attention after federal officials previously blocked it from publication in the CDC’s flagship journal. On June 23, the paper appeared instead in JAMA Network Open, shifting the dispute from an internal government review process to a public scientific debate.
Study moved from CDC publication to outside journal
The study was originally scheduled for release this spring in the CDC’s Morbidity and Mortality Weekly Report, commonly known as MMWR, according to the Associated Press and earlier reporting by The Washington Post. Instead, it was published Tuesday, June 23, in JAMA Network Open, a major peer-reviewed medical journal. The paper found the 2024-2025 COVID-19 vaccine was associated with about 55% effectiveness against COVID-19-related hospitalization and a 50% reduction in COVID-19-related emergency department and urgent care visits.
According to the Associated Press, CDC Chief Science Officer Althea Grant-Lenzy said the paper had cleared the agency’s Office of Science before it was flagged by acting CDC Director Jay Bhattacharya. She said the decision did not necessarily mean the paper would never be published, but it delayed release while concerns were raised about the study’s design. The authors then took the work to an outside journal.
JAMA’s publication gave the study a formal peer-reviewed outlet after weeks of scrutiny around why it was held back internally. The paper used a test-negative design, a common method in vaccine effectiveness research that compares vaccination status among patients seeking care for similar respiratory illness symptoms. Supporters of that approach said it remains one of the most practical tools for measuring real-world vaccine performance as viral strains and immunity patterns continue to change.
This is a national federal health story, not one tied to a single state or city, and no state-specific service changes were announced alongside the publication. The study itself drew on hospitalized adult patients at 26 hospitals in 20 U.S. states, according to JAMA Network Open, which gives it a broad multi-state footprint rather than a local or regional focus.
What is confirmed is that the paper is now publicly available through a major outside journal after it did not run in MMWR as first planned. What is not yet known is whether the CDC will separately publish its own version, issue a related summary, or change any internal publication procedures in response to the controversy. Federal health officials also have not announced any state-by-state rollout, advisory, or location-based impact tied directly to this study’s publication.
For readers, the immediate effect is informational rather than operational. There is no new vaccine mandate, no newly announced distribution program, and no published list of affected facilities because the dispute centered on scientific publication, not access to shots. The significance lies in where the findings appeared and how the public learned about them, not in any immediate change to local clinic operations.
The dispute centered on methodology. An HHS spokesman said in April that the manuscript was not accepted for publication in MMWR because of concerns about the approach used to estimate vaccine effectiveness, according to AP and Reuters-syndicated reporting. That method, the test-negative design, examines patients who sought hospital or emergency care for respiratory illness and compares COVID-19 test results by vaccination status.
Many outside public health researchers defended that design as longstanding and widely used. AP reported that papers using similar methods have appeared in journals including Pediatrics and The New England Journal of Medicine. A commentary published alongside the JAMA paper by Emory University biostatistician Natalie Dean said continued estimates of vaccine effectiveness remain important as immunity shifts and new strains emerge.
What comes next is likely to be measured in scientific and administrative terms rather than immediate public-facing policy. The publication does not settle the internal disagreement over CDC review standards, but it does place the findings into the peer-reviewed record. For now, the clearest verified development is that a study once stopped at the agency level is now available in a major medical journal with its core conclusions intact.